Verline buys ZSPH 70.56: ZS Pharma does not intend to comment additional on market speculation or disclose any developments unless and until it otherwise deems additional disclosure is appropriate or required.

ZS Pharma regularly and routinely explores opportunities with various planned partners and will continue to do so. ZS Pharma, Inc. (ZSPH) stated that it has take partd in preliminary discussions with Actelion Ltd. (ALIOF) regarding a potential planned transaction. The total market capitalization remained 361.13 Million. The warrants are exercisable for five years at $6 per share. All forward-looking statements are qualified in their entirety by this cautionary statement and speak only as of the date of this press release.


Tarah:
These discussions may or may not lead to any transaction.

Adele:
ZS Pharma regularly and routinely explores opportunities with various strategic partners and will continue to do so.

Rosa:
ZS Pharma issued a similar statement minutes later.

Eulalia:
The company has moved its headquarters from Coppell, Texas, to San Mateo, Calif.

Amira:
An everyday investor does not have the time or the required skill-set to carry out an in-depth analysis of equities and identify companies with the best future prospects like a fund with the knowledge and resources of Scopia Capital can.

Teri:
Its main candidate ZS-9 is in Phase III development and treats hyperkalemia.

Jeffie:
ZS Pharma is focused on developing non-absorbed drugs to treat renal, cardiovascular, and metabolic diseases.

Rossie:
The rumors took hold when the company cancelled its presentation at a Citi investor conference.

Tyisha:
The $1.53 billion biopharmaceutical company ZS Pharma Inc (NASDAQ:ZSPH) has seen a surge in volume today as investors took positions in the company sensing a possible acquisition or other major news development.

Loretta:
ZS Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.

Zs Pharma Inc. (NASDAQ:ZSPH)
//stockhand.net/us/?q=nasdaq%3Azsph&id=432810